Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada.
INTRODUCTION: The propensity for influenza viruses to mutate and recombine makes them both a familiar threat and a prototype emerging infectious disease. Emerging evidence suggests that the use of MF59-adjuvanted vaccines in older adults and young children enhances protection against influenza infec...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3215749?pdf=render |
| _version_ | 1819068485072846848 |
|---|---|
| author | David N Fisman Ashleigh R Tuite |
| author_facet | David N Fisman Ashleigh R Tuite |
| author_sort | David N Fisman |
| collection | DOAJ |
| description | INTRODUCTION: The propensity for influenza viruses to mutate and recombine makes them both a familiar threat and a prototype emerging infectious disease. Emerging evidence suggests that the use of MF59-adjuvanted vaccines in older adults and young children enhances protection against influenza infection and reduces adverse influenza-attributable outcomes compared to unadjuvanted vaccines. The health and economic impact of such vaccines in the Canadian population are uncertain. METHODS: We constructed an age-structured compartmental model simulating the transmission of influenza in the Canadian population over a ten-year period. We compared projected health outcomes (quality-adjusted life years (QALY) lost), costs, and incremental cost-effectiveness ratios (ICERs) for three strategies: (i) current use of unadjuvanted trivalent influenza vaccine; (ii) use of MF59-adjuvanted influenza vaccine adults ≥65 in the Canadian population, and (iii) adjuvanted vaccine used in both older adults and children aged < 6. RESULTS: In the base case analysis, use of adjuvanted vaccine in older adults was highly cost-effective (ICER = $2111/QALY gained), but such a program was "dominated" by a program that extended the use of adjuvanted vaccine to include young children (ICER = $1612/QALY). Results were similar whether or not a universal influenza immunization program was used in other age groups; projections were robust in the face of wide-ranging sensitivity analyses. INTERPRETATION: Based on the best available data, it is projected that replacement of traditional trivalent influenza vaccines with MF59-adjuvanted vaccines would confer substantial benefits to vaccinated and unvaccinated individuals, and would be economically attractive relative to other widely-used preventive interventions. |
| first_indexed | 2024-12-21T16:34:53Z |
| format | Article |
| id | doaj.art-ccf86bccb76d4c38933dec64889d07d6 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-21T16:34:53Z |
| publishDate | 2011-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-ccf86bccb76d4c38933dec64889d07d62022-12-21T18:57:15ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-01611e2742010.1371/journal.pone.0027420Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada.David N FismanAshleigh R TuiteINTRODUCTION: The propensity for influenza viruses to mutate and recombine makes them both a familiar threat and a prototype emerging infectious disease. Emerging evidence suggests that the use of MF59-adjuvanted vaccines in older adults and young children enhances protection against influenza infection and reduces adverse influenza-attributable outcomes compared to unadjuvanted vaccines. The health and economic impact of such vaccines in the Canadian population are uncertain. METHODS: We constructed an age-structured compartmental model simulating the transmission of influenza in the Canadian population over a ten-year period. We compared projected health outcomes (quality-adjusted life years (QALY) lost), costs, and incremental cost-effectiveness ratios (ICERs) for three strategies: (i) current use of unadjuvanted trivalent influenza vaccine; (ii) use of MF59-adjuvanted influenza vaccine adults ≥65 in the Canadian population, and (iii) adjuvanted vaccine used in both older adults and children aged < 6. RESULTS: In the base case analysis, use of adjuvanted vaccine in older adults was highly cost-effective (ICER = $2111/QALY gained), but such a program was "dominated" by a program that extended the use of adjuvanted vaccine to include young children (ICER = $1612/QALY). Results were similar whether or not a universal influenza immunization program was used in other age groups; projections were robust in the face of wide-ranging sensitivity analyses. INTERPRETATION: Based on the best available data, it is projected that replacement of traditional trivalent influenza vaccines with MF59-adjuvanted vaccines would confer substantial benefits to vaccinated and unvaccinated individuals, and would be economically attractive relative to other widely-used preventive interventions.http://europepmc.org/articles/PMC3215749?pdf=render |
| spellingShingle | David N Fisman Ashleigh R Tuite Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. PLoS ONE |
| title | Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. |
| title_full | Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. |
| title_fullStr | Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. |
| title_full_unstemmed | Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. |
| title_short | Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. |
| title_sort | estimation of the health impact and cost effectiveness of influenza vaccination with enhanced effectiveness in canada |
| url | http://europepmc.org/articles/PMC3215749?pdf=render |
| work_keys_str_mv | AT davidnfisman estimationofthehealthimpactandcosteffectivenessofinfluenzavaccinationwithenhancedeffectivenessincanada AT ashleighrtuite estimationofthehealthimpactandcosteffectivenessofinfluenzavaccinationwithenhancedeffectivenessincanada |